Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.
- SOURCES:
- Chris Snyder, professor of economics at Dartmouth College.
- David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania.
- Heather Stone, health science policy analyst at the Food & Drug Administration.
- Sarrin Chethik, senior policy analyst at the Market Shaping Accelerator.
- RESOURCES:
- Chasing My Cure: A Doctor’s Race to Turn Hope into Action; A Memoir, by David Fajgenbaum (2019).
- Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, by Michael Kremer and Rachel Glennerster (2016).
- Market Shaping Accelerator.
- CURE ID Registry.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Leave a Reply
You must be logged in to post a comment.